Boehringer and Gubra collaborate to discover peptide compounds for obesity treatment
Germany-based Boehringer Ingelheim has entered a collaboration and licensing agreement with Danish biotech company Gubra to develop new peptide compounds to treat obesity.
Source: Pharmaceutical Technology - Category: Pharmaceuticals Source Type: news
More News: Biotechnology | Denmark Health | Eating Disorders & Weight Management | Germany Health | Obesity | Pharmaceuticals